EUVIMEDEUVIMED entdecken
Vergleichsstudie

Quality of life and cost‐effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG ‐naïve non‐muscle‐invasive bladder cancer

Aviral Srivastava iD, Sameer Trivedi iD, Ujwal Kumar, Yashasvi Singh iD, Lalit Kumar, Sahil Data, Anil Kumar, Satya Narayan Sankhwar

BJU International · 2026

DOI: 10.1111/bju.70126 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift BJU International, 2026. Verfasst von Aviral Srivastava und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Deoxycytidine, Quality of Life, BCG Vaccine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare intravesical gemcitabine/docetaxel (Gem/Doce) vs standard‐of‐care bacillus Calmette–Guérin (BCG) in intermediate‐/high‐risk non‐muscle‐invasive bladder cancer (NMIBC), as patient‐reported physical‐psychological quality of life (QoL) and cost‐effectiveness estimation are pivotal to evaluate adjuvant intravesical treatments yet are rarely evaluated head‐on. Patients and Methods In a prospective per‐protocol analysis (Gem/Doce 39 patients; BCG 44 patients), survival endpoints (recurrence‐free survival [RFS], progression‐free survival [PFS]) and National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)‐graded adverse events (AEs) were recorded. QoL was assessed at baseline, post‐induction, and at 6 and 12 months using the European Organisation for Research and Treatment of Cancer Quality‐of‐Life Questionnaire‐30‐item core (EORTC QLQ‐C30) and 24‐item QLQ‐NMIBC (QLQ‐NMIBC24) and mapped to the EuroQoL five Dimensions five Levels (EQ‐5D‐5L) using an Indian tariff to estimate quality‐adjusted life years (QALYs). Direct medical costs were recorded, and incremental cost‐effectiveness ratios (ICERs) were calculated per QALY and recurrence/progression outcomes.

Results

Patients receiving Gem/Doce achieved higher 1‐year RFS (94.74% vs 75%, hazard ratio 0.44; P = 0.02) and PFS (100.00% vs 93.19%, P = 0.09). The AEs were fewer with Gem/Doce (12.82% vs 34.10%, P = 0.028); Grade 3 events occurred only with BCG (4.65%). Gem/Doce showed significantly higher global health, physical/role/emotional functioning and sexual health scores at 6–12 months, with reduced fatigue, urinary symptoms and intravesical‐treatment problems. Mean QALYs improved with Gem/Doce (0.8807 vs 0.7198), and with an ICER of ₹504 000 Indian Rupees ($6072 United States Dollars) per QALY – well within India's willingness‐to‐pay threshold and far below international benchmarks. Additional gains included +1.38 recurrence‐free months overall and +2.82 in high‐risk patients, achieved at acceptable incremental cost, indicating pragmatic cost profile against avoided recurrences and QoL gains.

Conclusions

Sequential Gem/Doce delivered optimal short‐term survival outcomes, favourable patient‐reported QoL and safety profile, and attractive cost per avoided recurrence/progression compared with BCG, supporting its adoption as a clinically and economically viable alternative in resource‐constrained NMIBC care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsDeoxycytidineQuality of LifeBCG VaccineAntineoplastic Combined Chemotherapy ProtocolsHumansGemcitabineCost-Benefit AnalysisDocetaxelFemaleMaleAgedMiddle AgedAdministration, IntravesicalProspective StudiesAdjuvants, ImmunologicNeoplasm InvasivenessNon-Muscle Invasive Bladder Neoplasms

Stichwörter der Autor:innen

BCGICERNMIBCgemcitabine/docetaxelquality‐of‐life

Substanzen

GemcitabineDeoxycytidineBCG VaccineDocetaxelAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.

ORCID-Profile: Aviral Srivastava, Sameer Trivedi, Yashasvi Singh

Zitieren

APA

Srivastava, A., Trivedi, S., Kumar, U., Singh, Y., Kumar, L., Data, S., Kumar, A., & Sankhwar, S. N. (2026). Quality of life and cost‐effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG ‐naïve non‐muscle‐invasive bladder cancer. BJU International. https://doi.org/10.1111/bju.70126

Vancouver

Srivastava A, Trivedi S, Kumar U, Singh Y, Kumar L, Data S, et al. Quality of life and cost‐effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG ‐naïve non‐muscle‐invasive bladder cancer. BJU International. 2026. doi:10.1111/bju.70126

BibTeX
@article{Srivastava2026,
  author = {Srivastava, Aviral and Trivedi, Sameer and Kumar, Ujwal and Singh, Yashasvi and Kumar, Lalit and Data, Sahil and Kumar, Anil and Sankhwar, Satya Narayan},
  title = {Quality of life and cost‐effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG ‐naïve non‐muscle‐invasive bladder cancer},
  journal = {BJU International},
  year = {2026},
  doi = {10.1111/bju.70126}
}
Kostenlos starten →